General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Plaque Psoriasis Management: Evaluating Non-Steroidal Treatments and Current Data Trends : Episode 8

Opinion

Video

July 18, 2024

Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

Author(s):

Alexa Hetzel, MS, PA-C,Andrew Mastro, MS, PA-C

Medical professionals discuss ongoing clinical trials and novel medications for the treatment of psoriasis.

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

EP: 7.TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 8.Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

EP: 9.Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

EP: 10.Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

EP: 11.Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

EP: 12.Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

EP: 13.When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

EP: 14.Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP: 15.Available Psoriasis, Patient Involvement, and Holistic Treatment

Related Videos

3 experts are featured in this series.

3 experts are featured in this series.

1 KOL is featured in this program

1 KOL is featured in this program

3 experts are featured in this series.

1 KOL is featured in this program

Ted Lain, MD, MBA, FAAD, is featured in this series.

Ted Lain, MD, MBA, FAAD, is featured in this series.

Related Content

Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care

November 20th 2024

Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition

November 19th 2024

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Quality of Life Severely Affected for Patients with GPP

November 5th 2024

Quality of Life Severely Affected for Patients with GPP

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

October 27th 2024

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

Related Content

Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care

November 20th 2024

Integrating Nonsteroidal Topical Therapies in Plaque Psoriasis Care

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition

November 19th 2024

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Quality of Life Severely Affected for Patients with GPP

November 5th 2024

Quality of Life Severely Affected for Patients with GPP

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

October 27th 2024

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.